Uğur Şahin, BioNTech CEO (Kay Nietfeld/picture-alliance/dpa/AP Images)
August 8, 2022 02:58 PM EDT
Pharma

De­spite falling Covid-19 sales, BioN­Tech main­tains '22 sales guid­ance

Paul Schloesser

Associate Editor

While Pfiz­er raked in al­most $28 bil­lion last quar­ter, its Covid-19 vac­cine part­ner BioN­Tech re­port­ed a rise in to­tal dose or­ders but a drop in …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

Bris­tol My­er­s' TYK2 in­hibitor suc­ceeds in pair of Phase 3 pso­ri­at­ic arthri­tis tri­als

A service from the Financial Times